A method of inhibiting anaphylaxis includes administering to a subject a composition comprising a first antibody, or fragment thereof, that binds to an allergen and a second antibody, or fragment thereof, that binds to the allergen, wherein the first antibody and the second antibody are from selected, epitope bins for an allergen that show the highest relative efficacy.

A method of inhibiting anaphylaxis includes administering to a subject a composition comprising a first antibody, or fragment thereof, that binds to an allergen and a second antibody, or fragment thereof, that binds to the allergen, wherein the first antibody and the second antibody are from selected, epitope bins for an allergen that show the highest relative efficacy.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the detection, treatment and prevention of allergies, such as those to peanut allergens.

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the detection, treatment and prevention of allergies, such as those to peanut allergens.

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to -glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti--glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti--glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti--glucan antibody.

A new platform method to purify plant-based monoclonal antibodies is provided. Such a method includes an antibody purification platform that involves a standardized procedure for the production of a wide array of different antibodies within a simplified context. The versatility of the overall purification process accords a one-size-fits-all approach for myriad antibody products and includes plant tissue harvesting, extraction and clarification, filtrate generation, a succession of column chromatography procedures, and buffer exposure to provide the desired monoclonal antibodies in proper filtered and purified form for further incorporation and/or use within medicaments and other formulations. Thus, the purified monoclonal antibodies produced thereby such a method are also encompassed within this invention.

A new platform method to purify plant-based monoclonal antibodies is provided. Such a method includes an antibody purification platform that involves a standardized procedure for the production of a wide array of different antibodies within a simplified context. The versatility of the overall purification process accords a one-size-fits-all approach for myriad antibody products and includes plant tissue harvesting, extraction and clarification, filtrate generation, a succession of column chromatography procedures, and buffer exposure to provide the desired monoclonal antibodies in proper filtered and purified form for further incorporation and/or use within medicaments and other formulations. Thus, the purified monoclonal antibodies produced thereby such a method are also encompassed within this invention.

The present invention provides a method of using increased levels of one or more biomarkers to identify subjects having non-celiac gluten sensitivity or non-celiac wheat sensitivity. The identification would aid the physician or health professional to determine a specific treatment for the patient, for example, a diet that eliminates wheat, rye, and/or barley. In one embodiment, the biomarkers are one or more of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2). The present invention also provides a method of using the same markers to monitor the response to treatment for non-celiac wheat sensitivity in a subject.